Providing mindfulness meditation for patients with depression and anxiety in a community pharmacy: A pilot study.

J. Perepelkin; Kristen Antunes; Luke Boechler; A. Remillard; Lindsay Mildenberger

doi:10.1016/j.japh.2018.10.017

Providing mindfulness meditation for patients with depression and anxiety in a community pharmacy: A pilot study.

J. Perepelkin, Kristen Antunes, Luke Boechler, A. Remillard, Lindsay Mildenberger

Journal of the American Pharmacists Association March 1, 2019 DOI: 10.1016/j.japh.2018.10.017 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Pre-post study Pilot study Peer reviewed
Sample size	12
Population	Patients with current anxiety or a history of anxiety, depression, or both
Intervention	Mindfulness meditation
Duration	8-week, once-per-week program
Topics	Anxiety Depression Meditation
Key points	A mindfulness meditation program delivered in a community pharmacy can reduce the severity of depression or anxiety for participants.

Abstract

Objective: The objective of this study was to assess the impact of mindfulness meditation offered in a community pharmacy on patients with current anxiety or a history of anxiety, depression, or both.

Setting: Community pharmacy clinical space located in a grocery store. PRACTICE DESCRIPTION An 8-week, once-per-week mindfulness meditation program for patients with anxiety or depression. PRACTICE INNOVATION A pharmacist provided mindfulness meditation within the clinical space in a community pharmacy. EVALUATION PHQ-9 and GAD-7 were used to assess prestudy and poststudy depression and anxiety severity, respectively. Items pertaining to participant demographics and experience in the program were also included.

Results: Twelve participants completed the study requirements. Three-quarters of participants experienced a reduction in the severity of their depression or anxiety, and no participant experienced an increase in the severity of his or her condition.

Conclusion: Findings from this study indicated that a mindfulness meditation program delivered in a community pharmacy and provided by a pharmacist for patients with depression or anxiety, or both, can result in a reduction in severity of their conditions for participants.

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study	Year	Design	Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression	2018	Clinical trial	n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD)	2006	Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder	2010	Open-label trial	n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male)	2020	Open-label pilot study	n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe...	2020	Open-label study

Citations in the library

Cited by 2

Cites 10

and 5 more in the library